Loading...

Bio-Path Holdings

Nasdaq:BPTH
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BPTH
Nasdaq
$45M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The last earnings update was 58 days ago. More info.


Add to Portfolio Compare Print
  • Bio-Path Holdings has significant price volatility in the past 3 months.
BPTH Share Price and Events
7 Day Returns
10%
NasdaqCM:BPTH
-5.7%
US Biotechs
-3.9%
US Market
1 Year Returns
-49%
NasdaqCM:BPTH
-7.9%
US Biotechs
1.4%
US Market
BPTH Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Bio-Path Holdings (BPTH) 10% -14.7% 729.4% -49% -96.7% -96.7%
US Biotechs -5.7% -8.7% -6.4% -7.9% 5.5% 10.5%
US Market -3.9% -3.6% 1.8% 1.4% 35.8% 40.8%
1 Year Return vs Industry and Market
  • BPTH underperformed the Biotechs industry which returned -7.9% over the past year.
  • BPTH underperformed the Market in United States of America which returned 1.4% over the past year.
Price Volatility
BPTH
Industry
5yr Volatility vs Market
Related Companies

BPTH Value

 Is Bio-Path Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Bio-Path Holdings. This is due to cash flow or dividend data being unavailable. The share price is $17.75.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Bio-Path Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Bio-Path Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:BPTH PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-14.38
NasdaqCM:BPTH Share Price ** NasdaqCM (2019-05-15) in USD $17.75
United States of America Biotechs Industry PE Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 19.35x
United States of America Market PE Ratio Median Figure of 3,087 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Bio-Path Holdings.

NasdaqCM:BPTH PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:BPTH Share Price ÷ EPS (both in USD)

= 17.75 ÷ -14.38

-1.23x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bio-Path Holdings is loss making, we can't compare its value to the US Biotechs industry average.
  • Bio-Path Holdings is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Bio-Path Holdings's expected growth come at a high price?
Raw Data
NasdaqCM:BPTH PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.23x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.15x
United States of America Market PEG Ratio Median Figure of 2,113 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Bio-Path Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Bio-Path Holdings's assets?
Raw Data
NasdaqCM:BPTH PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.79
NasdaqCM:BPTH Share Price * NasdaqCM (2019-05-15) in USD $17.75
United States of America Biotechs Industry PB Ratio Median Figure of 415 Publicly-Listed Biotechs Companies 3.11x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
NasdaqCM:BPTH PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:BPTH Share Price ÷ Book Value per Share (both in USD)

= 17.75 ÷ 1.79

9.91x

* Primary Listing of Bio-Path Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bio-Path Holdings is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Bio-Path Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Bio-Path Holdings has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BPTH Future Performance

 How is Bio-Path Holdings expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bio-Path Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.7%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Bio-Path Holdings expected to grow at an attractive rate?
  • Unable to compare Bio-Path Holdings's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Bio-Path Holdings's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Bio-Path Holdings's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:BPTH Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:BPTH Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:BPTH Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
NasdaqCM:BPTH Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -6 -9
2018-09-30 0 -7 -9
2018-06-30 0 -7 -8
2018-03-31 0 -8 -10
2017-12-31 0 -8 -8
2017-09-30 0 -7 -7
2017-06-30 0 -8 -6
2017-03-31 0 -8 -5
2016-12-31 0 -8 -7
2016-09-30 -8 -7
2016-06-30 -7 -7
2016-03-31 -6 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Bio-Path Holdings is high growth as no earnings estimate data is available.
  • Unable to determine if Bio-Path Holdings is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:BPTH Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Bio-Path Holdings Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:BPTH Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
NasdaqCM:BPTH Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -14.38
2018-09-30 -15.70
2018-06-30 -15.11
2018-03-31 -18.20
2017-12-31 -15.99
2017-09-30 -14.91
2017-06-30 -13.20
2017-03-31 -11.21
2016-12-31 -14.56
2016-09-30 -14.99
2016-06-30 -15.10
2016-03-31 -13.28

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Bio-Path Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Bio-Path Holdings's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Bio-Path Holdings's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Bio-Path Holdings's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Bio-Path Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Bio-Path Holdings has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BPTH Past Performance

  How has Bio-Path Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Bio-Path Holdings's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Bio-Path Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Bio-Path Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Bio-Path Holdings's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Bio-Path Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Bio-Path Holdings Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:BPTH Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -8.58 3.38 4.60
2018-09-30 0.04 -8.84 3.39 5.49
2018-06-30 0.04 -8.23 3.55 4.73
2018-03-31 0.04 -9.58 3.54 5.39
2017-12-31 0.04 -8.06 3.52 5.48
2017-09-30 0.01 -7.27 3.44 5.04
2017-06-30 0.01 -6.36 3.22 5.77
2017-03-31 0.01 -5.28 3.14 5.48
2016-12-31 0.01 -6.75 3.01 5.47
2016-09-30 -6.84 2.88 5.39
2016-06-30 -6.78 2.72 4.07
2016-03-31 -5.96 2.53 3.45
2015-12-31 -5.47 2.47 3.02
2015-09-30 -5.61 2.74 2.89
2015-06-30 -5.25 2.93 2.33
2015-03-31 -5.39 3.12 2.29
2014-12-31 -4.52 2.72 1.83
2014-09-30 -3.71 2.19 1.54
2014-06-30 -3.96 2.29 1.68
2014-03-31 -3.11 1.78 1.35
2013-12-31 -3.27 1.63 1.63
2013-09-30 -2.91 1.55 1.36
2013-06-30 -2.36 0.98 1.37
2013-03-31 -2.72 0.99 1.38
2012-12-31 -2.58 0.99 1.25
2012-09-30 -2.95 0.95 1.31
2012-06-30 -2.62 1.03 0.90

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Bio-Path Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Bio-Path Holdings has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Bio-Path Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Bio-Path Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Bio-Path Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BPTH Health

 How is Bio-Path Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Bio-Path Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Bio-Path Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Bio-Path Holdings has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Bio-Path Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Bio-Path Holdings has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Bio-Path Holdings Company Filings, last reported 4 months ago.

NasdaqCM:BPTH Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 1.22 0.00 1.00
2018-09-30 2.99 0.00 2.29
2018-06-30 4.74 0.00 2.58
2018-03-31 6.28 0.00 4.28
2017-12-31 8.07 0.00 5.97
2017-09-30 6.55 0.00 4.62
2017-06-30 8.86 0.00 6.18
2017-03-31 8.09 0.00 7.11
2016-12-31 8.24 0.00 9.38
2016-09-30 9.38 0.00 11.30
2016-06-30 6.33 0.00 4.22
2016-03-31 8.05 0.00 6.47
2015-12-31 9.82 0.00 8.85
2015-09-30 11.19 0.00 9.85
2015-06-30 12.60 0.00 11.08
2015-03-31 13.63 0.00 12.45
2014-12-31 14.92 0.00 13.86
2014-09-30 16.00 0.00 14.64
2014-06-30 17.03 0.00 15.72
2014-03-31 18.18 0.00 16.82
2013-12-31 4.78 0.00 3.55
2013-09-30 5.58 0.00 4.10
2013-06-30 3.48 0.00 1.93
2013-03-31 1.68 0.00 0.29
2012-12-31 2.01 0.00 0.53
2012-09-30 1.80 0.00 0.33
2012-06-30 1.92 0.00 0.16
  • Bio-Path Holdings has no debt.
  • Bio-Path Holdings has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Bio-Path Holdings has less than a year of cash runway based on current free cash flow.
  • Bio-Path Holdings has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.3% each year.
X
Financial health checks
We assess Bio-Path Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Bio-Path Holdings has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BPTH Dividends

 What is Bio-Path Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Bio-Path Holdings dividends.
If you bought $2,000 of Bio-Path Holdings shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Bio-Path Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Bio-Path Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:BPTH Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.5%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1997 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:BPTH Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Bio-Path Holdings has not reported any payouts.
  • Unable to verify if Bio-Path Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Bio-Path Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Bio-Path Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Bio-Path Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Bio-Path Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Bio-Path Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BPTH Management

 What is the CEO of Bio-Path Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Peter Nielsen
COMPENSATION $671,927
AGE 69
TENURE AS CEO 11.3 years
CEO Bio

Mr. Peter H. Nielsen, MBA, is a Co-Founded Bio-path Holdings, Inc. in 2007 and has been its Chairman, President, Chief Executive Officer, Chief Financial Officer and Treasurer since 2008. Mr. Nielsen licensed technology and targets from The University of Texas, MD Anderson Cancer Center and coordinated preclinical development, optimization and manufacturing of Bio-Path’s lead drug candidate, prexigebersen. Over the next ten years, Mr. Nielsen led the clinical advancement of prexigebersen into Phase II studies, the introduction of additional pipeline candidates and the Company’s public market debut. Mr. Nielsen served as Chief Accounting Officer at Bio-path Holdings, Inc. He co-founded Interpath Pharmaceuticals, Inc. in 2001 and serves as its Chief Executive Officer. He has a broad management background in senior management, leading turnarounds of several large companies. He has experience in finance, product development, cost and investmentanalysis, manufacturing and planning. Mr. Nielsen served as Chief Financial Officer of Omni Energy Services Corp. He worked with several otherbiotech companies developing and executing on strategies for growth and is a Director of Synthecon, Inc. He has been Director of Bio-path Holdings, Inc. since 2008. Mr. Nielsen was a Lieutenant in the U.S. Naval Nuclear Power program where he was Director of the Physics Dept. and was employed at Ford Motor Company inproduct development. He holds engineering, mathematics and M.B.A. finance degrees from the University of California at Berkeley.

CEO Compensation
  • Peter's compensation has increased whilst company is loss making.
  • Peter's remuneration is higher than average for companies of similar size in United States of America.
Management Team

Peter Nielsen

TITLE
Co-Founder
COMPENSATION
$672K
AGE
69
TENURE
11.3 yrs

Douglas Morris

TITLE
Co-Founder
COMPENSATION
$91K
AGE
62
TENURE
12.3 yrs

Anthony Price

TITLE
Director of Finance and Accounting

Alan MacKenzie

TITLE
Consultant

Thomas Walker

TITLE
Consultant

Jeffery Lancet

TITLE
Consultant

Victoria Lake

TITLE
Regulatory Consultant
Board of Directors Tenure

Average tenure and age of the Bio-Path Holdings board of directors in years:

2.3
Average Tenure
62
Average Age
  • The average tenure for the Bio-Path Holdings board of directors is less than 3 years, this suggests a new board.
Board of Directors

Peter Nielsen

TITLE
Co-Founder
COMPENSATION
$672K
AGE
69
TENURE
11.3 yrs

Douglas Morris

TITLE
Co-Founder
COMPENSATION
$91K
AGE
62
TENURE
12.3 yrs

Heath Cleaver

TITLE
Director
COMPENSATION
$57K
AGE
45
TENURE
5.3 yrs

Jorge Cortes

TITLE
Chairman of the Scientific Advisory Board
TENURE
3.8 yrs

Mark Colonnese

TITLE
Director
COMPENSATION
$58K
AGE
63
TENURE
1.8 yrs

D. Hooper

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs

Paul Aubert

TITLE
Director
COMPENSATION
$48K
AGE
48
TENURE
0.4 yrs

Anas Younes

TITLE
Member of Scientific Advisory Board
TENURE
0.3 yrs

Jason Fleming

TITLE
Member of Scientific Advisory Board
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
23. Jan 19 Sell Armistice Capital LLC Company 18. Jan 19 18. Jan 19 -64,457 $2.66 $-171,643
X
Management checks
We assess Bio-Path Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Bio-Path Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BPTH News

Simply Wall St News

What Kind Of Investor Owns Most Of Bio-Path Holdings, Inc. (NASDAQ:BPTH)?

The big shareholder groups in Bio-Path Holdings, Inc. … Bio-Path Holdings is a smaller company with a market capitalization of US$39m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company.

Simply Wall St -

Did Changing Sentiment Drive Bio-Path Holdings's Share Price Down A Disastrous 99%?

We don't think Bio-Path Holdings's revenue of US$37,000 is enough to establish significant demand. … It seems likely some shareholders believe that Bio-Path Holdings has the funding to invent a new product before too long. … Bio-Path Holdings had net cash of just US$1.3m when it last reported (September 2018).

Simply Wall St -

Does Bio-Path Holdings, Inc.'s (NASDAQ:BPTH) CEO Salary Reflect Performance?

In 2008 Peter Nielsen was appointed CEO of Bio-Path Holdings, Inc. … First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Peter Nielsen's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Bio-Path Holdings Inc (NASDAQ:BPTH): Time For A Financial Health Check

The direct benefit for Bio-Path Holdings Inc (NASDAQ:BPTH), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … However, the trade-off is BPTH will have to adhere to stricter debt covenants and have less financial flexibility. … Does BPTH's growth rate justify its decision for financial flexibility over lower cost of capital.

Simply Wall St -

Is Bio-Path Holdings Inc's (NASDAQ:BPTH) CEO Being Overpaid?

This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Peter Nielsen's Compensation Compare With Similar Sized Companies. … As you can see, Peter Nielsen is paid more than the median CEO pay at companies of a similar size, in the same market

Simply Wall St -

How Financially Strong Is Bio-Path Holdings Inc (NASDAQ:BPTH)?

Bio-Path Holdings Inc (NASDAQ:BPTH), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Is BPTH growing fast enough to value financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.

Simply Wall St -

How Should You Think About Bio-Path Holdings Inc's (NASDAQ:BPTH) Risks?

A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … With a beta of 2.76, Bio-Path Holdings is a stock that tends to experience more gains than the market during a growth phase and also a bigger reduction in value compared to the market during a broad downturn. … Based on this beta value, BPTH may be a stock for investors with a portfolio mainly made up of low-beta stocks.

Simply Wall St -

Bio-Path Holdings Inc (NASDAQ:BPTH): Does The -19.42% Earnings Drop Reflect A Longer Term Trend?

View our latest analysis for Bio-Path Holdings Commentary On BPTH's Past Performance For the purpose of this commentary, I like to use data from the most recent 12 months, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. … NasdaqCM:BPTH Income Statement Apr 11th 18 We can further examine Bio-Path Holdings's loss by looking at what the industry has been experiencing over the past few years. … Though Bio-Path Holdings's past data is helpful, it is only one aspect of my investment thesis.

Simply Wall St -

Is It Time To Buy Bio-Path Holdings Inc (NASDAQ:BPTH)?

Bio-Path Holdings Inc (NASDAQ:BPTH), a pharmaceuticals company based in United States, saw significant share price volatility over the past couple of months on the NasdaqCM, rising to the highs of $3.1 and falling to the lows of $1.82. … I find that Bio-Path Holdings’s ratio of 2.78x is trading slightly above its industry peers’ ratio of 2.65x, which means if you buy Bio-Path Holdings today, you’d be paying a relatively fair price for it. … And if you believe Bio-Path Holdings should be trading in this range, then there isn’t really any room for the share price grow beyond what it’s currently trading.

Simply Wall St -

Is It Time To Buy Bio-Path Holdings Inc (BPTH)?

So, could BPTH still be trading at a low price relative to its actual value? … The stock’s ratio of 3.3x is currently trading slightly below its industry peers’ ratio of 4.9x, which means if you buy BPTH today, you’d be paying a relatively fair price for it. … If you’ve been keeping tabs on BPTH, now may not be the most advantageous time to buy, given it is trading around its fair value.

Simply Wall St -

BPTH Company Info

Description

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and myelodysplastic syndrome, as well as in Phase IIa clinical trials for the treatment of chronic myeloid leukemia. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Details
Name: Bio-Path Holdings, Inc.
BPTH
Exchange: NasdaqCM
Founded: 2007
$44,503,492
2,507,239
Website: http://www.biopathholdings.com
Address: Bio-Path Holdings, Inc.
4710 Bellaire Boulevard,
Suite 210,
Bellaire,
Texas, 77401,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM BPTH Common Stock Nasdaq Capital Market US USD 15. Feb 2008
DB IBPB Common Stock Deutsche Boerse AG DE EUR 15. Feb 2008
Number of employees
Current staff
Staff numbers
8
Bio-Path Holdings employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/16 02:04
End of day share price update: 2019/05/15 00:00
Last estimates confirmation: 2017/03/15
Last earnings filing: 2019/03/19
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.